Skip to main content

Table 5 Efficacy and/or immune responses of experimental vaccines (subunit, membrane proteins, culture supernate) against Mycoplasma hyopneumoniae tested in pigs.

From: Perspectives for improvement of Mycoplasma hyopneumoniae vaccines in pigs

Antigen Vaccine type Adjuvant/carrier Route Nb of vaccinations Challenge infection Decrease of Humoral response CMI responseb Other/comments References
Lung lesions Clinical signs M. hyopneumoniae numbers Serum BALF c
P97 Subunit Complete Freund’s adjuvant IM 2 Yes No No   Yesd     [98]
J strain Membrane proteins Five different adjuvantse IM-IP 2 Yes Yese    IgG, IgA IgA, IgG   No effect on ADG; Humoral response in BALF: only after challenge, greater in IM groups [48]
Strain 1986–1 Cell-free culture supernate Al(OH)3 IM 2 Yes Yes   Yes IgG (low)     [99]
Strain 1986–1 Cell-free culture supernate Al(OH)3 IM 2 Yes Yes   Yes   IgA, IgG   Less macrophages, lymphocytes and TNFα in lungs
Humoral response in BALF only after challenge
[100]
P97 (RR1) a Chimeric subunit with Pseudomonas exotoxin A   SC (mice)-IM (pigs) 2 No     IgG     [101]
P97 (R1R2) Chimeric subunit with N-terminal region A. pleuropneumoniae ApxIII Freund’s adjuvant (mice), Al(OH)3 (pigs) SC (mice)-IM (pigs) 2 Yes (pigs) Yes Yes   IgG1, IgG2a (mice)   Higher IFN-γ and IL-4 (mice) Also protection against A. pleuropneumoniae [102]
P97, P42, NrdF Chimeric subunit LTBf IM-IN 2 Yes No No No IgG IgA   IgA in BALF only after challenge
Commercial vaccine: lower serological response, better protection
[21]
P102 and 8 fragments of P97 /P102 paralogs Subunit Al(OH)3 and polymer based (Montanide™) IM 3 Yes No No No IgG No IgA   Less cilia damage, less Il-1, Il-6, TNFα in BALF
Commercial vaccine: lower serological response, better protection
[52]
  1. IM, Intramuscular; SC, Subcutaneous; IN, Intranasal; IP, intraperitoneal.
  2. aStudy was done in pigs and mice.
  3. bCMI response was tested by stimulation of splenocytes.
  4. cBALF bronchoalveolar lavage fluid.
  5. dtested by Western blotting for reactivity with whole cell lysates.
  6. eThe membrane preparations were formulated with one of the following adjuvants: 1) Auspharm oil, 2) Alhydrogel, 3) Algammulin, 4) DEAE dextran with Auspharm oil, 5) DEAE dextran with mineral oil. Lung lesions were significantly reduced with all formulations compared to non-vaccinated pigs, but there were no significant differences between the formulations.
  7. fLTB B subunit of heat-labile enterotoxin of E. coli.